Medincell S Ais A Pharmaceutical Company Located In Jacoufranceestablished In 2002The Company Specializes In Developing Long Acting Injectable Products Using Its Proprietary Bepoatechnologythis Innovative Approach Allows For The Controlled Release Of Active Pharmaceutical Ingredientsenhancing Patient Compliance And Treatment Effectiveness While Minimizing Environmental Impact Medincell S Portfolio Includes A Range Of Long Acting Injectable Medicines Across Various Therapeutic Areasthe Bepoatechnology Ensures That Medications Are Delivered At Optimal Therapeutic Doses Over Extended Periodsreducing The Frequency Of Administrationas Of March 312024The Company Has Two Products In Phase Iii Clinical Development And Two In Preclinical Developmentall Designed To Be Fully Bioresorbable Listed On Euronext Parismedincell Has A Diverse Workforce Of Over 130 Employees From More Than 25 Nationalitiesthe Company Has Raised Approximately $28 1 Million In Funding And Has A Market Capitalization Of Around $0 18 Billionmedincell S Sales Span Several Regionsincluding Israelthe United Statesswitzerlandgermanyand Francereflecting Its Global Reach In Improving Healthcare Outcomes
